History

FUJIFILM Toyama Chemical Co., Ltd.

Year Month History
2018 Oct. FUJIFILM RI Pharma merged TOYAMA CHEMICAL.
Company name changed to FUJIFILM Toyama Chemical Co., Ltd.
2019 Jan. Launch of medication verification system "PROOFIT 1D"
2019 Feb. Launch of ORAVI® Mucoadhesive Tablets 50mg for Oropharyngeal Candidiasis in Japan
2019 Dec. Completion of manufacturing facility for liposome formulations in Toyama Second Factory
2021 Feb. Approval of PEMETREXED INTRAVENOUS INFUSION 100mg/500mg "TOWA"
2021 Apr. Transfer of rights to IOPROMIDE Injection and IOPROMIDE Injection Syringe to Bayer Yakuhin, Ltd. in Japan
2021 Jun. Approval of LUTATHERA® Ingection and LYSAKARE® Injection  
2021 Jul. Succession of the constant-temperature transportation device business to TOHO PHARMACEUTICAL CO., LTD. 
2021 Sep. Approval of Raiatt MIBG-I 131 Injection
2021 Nov. Transfer of marketing rights for ORAVI® Mucoadhesive Tablets 50mg to Hisamitsu Pharmaceutical
2022 Mar. Succession of the radiopharmaceutical business to PDRadiopharma Inc.
Year History
1936 Toyama Chemical Co., Ltd., established around the business of Toyama Chemical Research Laboratory
1961 Head office relocated from Toyama to Nihonbashi, Tokyo
Listed on the second section of the Tokyo Stock Exchange
1970 General Research Laboratory completed
1971 Factory for the manufacture of injectable products completed
1972 Listed on the first section of the Tokyo Stock Exchange
First phase of pharmaceutical factory completed
1975 No. 2 Research Laboratory completed
Second phase of pharmaceutical factory completed
1978 Head office relocated from Nihonbashi to Shinjuku, Tokyo
1979 Approval of PENTCILLIN injection and intramuscular
1980 No. 3 Research Laboratory completed
1981 Approval of ABOVIS capsules
Toyama Second Factory established
1982 Approval of BAXO capsules
1985 No. 5 Research Laboratory completed
1986 Approval of BAXO ointment
1987 Approval of TOMIRON tablet
1988 Approval of BAXO suppositories
1989 No. 1 Research Laboratory completed
1990 Approval of OZEX tablet
Approval of TOMIRON fine granules
1998 Pharmaceutical factory and distribution wing completed
1999 LUPRAC tablet introduced in Japan
2002 HALOSPOR intravenous introduced in Japan
Agreed on a strategic capital and business alliance with Taisho Pharmaceutical Co., Ltd.
Approval of PASIL intravenous drip
Taisho Toyama Pharmaceutical Co., Ltd. established
Approval of PENTCILLIN intravenous bag
2006 Approval of OZEX ophthalmic solution
No. 6 Research Laboratory completed
2007 Approval of GENINAX tablet
2008 Agreed on a strategic capital and business alliance between FUJIFILM Holdings Corporation, Taisho Pharmaceutical Co., Ltd. and Toyama Chemical Co., Ltd.
Delisted on the first section of the Tokyo Stock Exchange
Approval of ZOSYN intravenous
2009 Approval of OZEX fine granules
2012 No. 7 Research Laboratory completed
Approval of KOLBET tablet
2013 Factory for the manufacture of injectable products completed
2014 Factory for the manufacture of injectable bag products completed
Approval of AVIGAN tablet
Approval of ZOSYN intravenous bag
2018 Transfer of rights to KOLBET tablet to Eisai Co., Ltd. in Japan
Toyama Chemical Co., Ltd. became 100% subsidiary of FUJIFILM Corporation